AG-013736 In Combination With Docetaxel Versus Docetaxel Alone For Patients With Metastatic Breast Cancer

Completed · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Breast Neoplasms

In brief

The primary purpose of the study is to determine the time to progression of the combination of study drug (AG-013736) and docetaxel versus docetaxel alone in patients who have not received prior chemotherapy for metastatic breast cancer. The secondary purpose of the study is to determine the dose of study drug that can be given with docetaxel administered on an every 3 week schedule.

Key facts

Study ID

NCT00076024

Run by

Pfizer

People needed

174

Starts

2004-02-01

Expected to finish

2008-11-01

Last updated by the study team

2012-06-26

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Female patients with histologically/cytologically proven metastatic breast carcinoma (stage IV, or recurrent with local or regional spread or distant metastatic disease)
• Adequate bone marrow, liver, and renal function

You may not qualify if…

• Adjuvant chemotherapy given in the past 12 months
• Uncontrolled brain metastases

Where it is running

• Pfizer Investigational Site — Tucson, Arizona, United States
• Pfizer Investigational Site — Berkeley, California, United States
• Pfizer Investigational Site — Montebello, California, United States
• Pfizer Investigational Site — Monterey Park, California, United States
• Pfizer Investigational Site — San Francisco, California, United States
• Pfizer Investigational Site — San Gabriel, California, United States
• Pfizer Investigational Site — Whittier, California, United States
• Pfizer Investigational Site — Jacksonville, Florida, United States
• Pfizer Investigational Site — Jacksonville, Florida, United States
• Pfizer Investigational Site — Jacksonville, Florida, United States
• Pfizer Investigational Site — Jacksonville Beach, Florida, United States
• Pfizer Investigational Site — Melbourne, Florida, United States
• Pfizer Investigational Site — Orange Park, Florida, United States
• Pfizer Investigational Site — Palatka, Florida, United States
• Pfizer Investigational Site — Saint Augustine, Florida, United States
• Pfizer Investigational Site — Chicago, Illinois, United States
• Pfizer Investigational Site — Chicago, Illinois, United States
• Pfizer Investigational Site — Zion, Illinois, United States
• Pfizer Investigational Site — Boston, Massachusetts, United States
• Pfizer Investigational Site — Ann Arbor, Michigan, United States
• Pfizer Investigational Site — Stony Brook, New York, United States
• Pfizer Investigational Site — Cleveland, Ohio, United States
• Pfizer Investigational Site — Corvallis, Oregon, United States
• Pfizer Investigational Site — Edmonton, Alberta, Canada
• Pfizer Investigational Site — Tucson, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.